Production (Stage)
Oruka Therapeutics, Inc.
ORKA
$12.58
$0.393.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | ||
|---|---|---|---|---|---|
| Net Income | 37.11% | -16.66% | -28.68% | -214.30% | |
| Total Depreciation and Amortization | -13.51% | 68.18% | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -26.18% | -59.49% | 1,427.87% | 701.16% | |
| Change in Net Operating Assets | -160.27% | 151.72% | -192.51% | 54.20% | |
| Cash from Operations | 13.32% | 13.45% | -152.13% | -6,467.26% | |
| Capital Expenditure | 63.07% | 79.42% | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | 111.91% | -- | -- | -- | |
| Cash from Investing | 111.91% | -210,407.31% | -- | -- | |
| Total Debt Issued | -- | -199.46% | -- | -100.00% | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -- | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -93.12% | 510.89% | -- | |
| Cash from Financing | -- | -90.48% | 26,767.28% | -105.69% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 106.40% | -186.85% | 3,235.43% | -145.50% | |